Therapeutic potential of RvD1 in metabolic complications associated with obesity
Persistent activation of the innate immune system is known to influence the risk of developing metabolic complications associated with obesity.
A metabolic lipidomic analysis was carried out (using liquid chromatography–mass spectrometry) to study the therapeutic potential of the specialised pro-resolving mediator (SPM), resolvin D1 (RvD1), in the inflammation of visceral fat tissues in obese patients. The analysis identified an imbalanced production of SPM (resolvins D and E, protectin D1, maresin 1 and lipoxins) compared to inflammatory lipid mediators (leukotriene B4 and prostaglandins). At the same time, overactivation of the interleukin 10 (IL-10) signalling pathway was observed. Incubation of this inflamed adipose tissue from obese patients with RvD1 limited this overactivation and promoted inflammation resolution.
These data show that RvD1 can modulate quantitative and qualitative responses to IL-10 in inflamed tissues, findings that could have therapeutic implications in metabolic complications associated with obesity.